New Current Report Filed with the SEC Disclosing Receipt of a Notice of Delisting, the Failure to Satisfy a Continued Listing Rule or Standard or the Transfer of a Listing: 8-K – Onconova Therapeutics, Inc. (0001130598) (Filer)

A current report on Form 8-K was just filed with the U.S. Securities & Exchange Commission (SEC) disclosing receipt of a notice of delisting, the failure to satisfy a continued listing rule or standard or the transfer of a listing. Details of the current report are:

8-K Onconova Therapeutics, Inc. (0001130598) (Filer)

Filed: 2016-02-17 AccNo: 0001104659-16-097740 Size: 139 KB

Item 2.05: Cost Associated with Exit or Disposal Activities

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item 9.01: Financial Statements and Exhibits

Filing Date: 2016-02-17T17:00:42-05:00

This is a breaking news story. You can access the complete current report through the SECs Edgar system: http://www.sec.gov/Archives/edgar/data/1130598/000110465916097740/0001104659-16-097740-index.htm

Share this:Like this:Like Loading…

http://chapter11cases.com/2016/02/17/new-current-report-filed-with-the-sec-disclosing-receipt-of-a-notice-of-delisting-the-failure-to-satisfy-a-continued-listing-rule-or-standard-or-the-transfer-of-a-listing-8-k-onconova-therapeutics-2/